US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice

Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced the publication by co-founder Helena Edlund of a new study demonstrating the prevention and reversal of gene expression and epigenetic changes to beta cells in diet-induced obese mice. Treatment with O304 prevented genome-wide gene expression changes associated with high fat diet and remodelled active and repressive chromatin markers in beta cells, the cells responsible for producing the body’s insulin.  Glucose control was restored in the animals and markers of stress were reduced and

Betagenon co-founder publishes study demonstrating that pan-AMPK activator O304 acts as an exercise mimetic in aged mice

Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced the publication by co-founder Prof. Helena Edlund of a new study demonstrating that in aged mice the pan-AMPK activator O304 improves cardiac function and exercise capacity, while preventing and reversing age-associated hyperinsulinemia and insulin resistance. O304 thus functions as an exercise mimetic and could therefore have a similar therapeutic potential in aged humans and improve quality of life. The data are published in Communications Biology, a member of the Nature family of

Betagenon AB announces investment and collaboration with Hong Kong-based MCG Technology Group Ltd

Betagenon AB, a Sweden-based biotech company focused on development of AMPK activator compounds, and MCG Technology Group Ltd, a Hong Kong-based biotech investment group, today announced that MCG Technology Group will invest in and collaborate with Betagenon.MCG Technology Group will invest 2M USD in exchange for Betagenon equity.  Additionally, both parties will collaborate to test Betagenon’s AMPK activator compound in patients with heart failure with preserved ejection fraction (HFpEF).  In return for further equity in Betagenon, the study will be delivered via MCG Technology Group’s

Betagenon AB announces new CEO and new Chairman of the Board

Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced that James Hall BM, BCh, D.Phil has joined this month as CEO.  Dr. Hall brings extensive senior healthcare and life science experience, including 12 years with AstraZeneca.  While there, he held a number of commercial, R&D and Business Development roles, including VP Global Marketing for the CV/GI Therapy Area, Global Product VP for Crestor and VP Evaluation for the CV/Metabolism/Renal Therapy Area.  Prior to this he was a member of the Pharmaceutical/Medical Products practice at

Start of bridging pharmacokinetic and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator O304

Betagenon /Balticgruppen Bio AB announces the start of a bridging PK and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator compound O304.In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O304 was administered as a suspension and with limited oral bioavailability. A novel formulation of O304 has now been developed that unexpectedly improved oral bioavailability markedly in animals. A patent application (matter of composition) with priority date to 2039 without extensions

China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program

Balticgruppen Bio, the Umeå based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has closed a funding round with China based asset management firm Ivy Capital granting the company 3 MUSD of funding. Betagenon has successfully taken its first-in-class PAN-AMPK-activator O304, a novel small molecule for treatment of cardio-metabolic disorders, through pre-clinical and clinical Phase I and Phase IIa testing as well as long-term toxicological studies in animals. The results show that beneficial cardiovascular and metabolic effects

Dr. Jan M. Lundberg, former head of R&D at AstraZeneca and Eli Lilly has joined Betagenon’s board of directors

Dr. Jan M Lundberg brings extensive industrial competence to Betagenon"Jan’s executive industrial experience as head of R&D at two major pharmaceutical companies, and his involvement the discovery, development and approval of more than 20 products makes his experience and competence invaluable to Betagenon. As a member of the board of directors and as an investor, Jan will add significant strategic competence to the further clinical development and out-licensing of our First-in-Class PAN-AMPK activator O304." said Thomas Edlund, CEO of Betagenon AB. At Eli Lilly Dr. Lundberg, as head

AMPK activator O304 A novel potential treatment for diabetic kidney disease

Diabetic kidney diseaseGlobally ~40% of type 2 diabetes (T2D) patients develop diabetic kidney disease (DKD), and diabetes is the leading cause of end stage renal disease, requiring dialysis or a kidney transplant. Standard of care consists of antihypertensive medication (ACEi/ARB inhibitors), and regulation of the blood sugar level as part of regular diabetes care, but with very limited efficacy. Thus, in addition to risks, personal suffering, and reduced quality of life for millions of people, DKD is associated with billions in costs to society. No new drugs - SGLT2 inhibitors?

Betagenon/Baltic Bio announces positive results from a 28 day Phase IIa trial of the first-in-class AMPK activator O304 in Type 2 Diabetics

O304 reduces significantly fasting plasma glucose (FPG) in type 2 diabeticsThe main study results are not yet finalized. Review of the initial data showed that a number of patients who were included based on HbA1c at screening, had FPG below 7 mM or above 13.3 mM at day 1, and that the data analysis of FPG required a post hoc analysis plan.In type 2 diabetic patients on Metformin with FPG >7 mM and < 13.3 mM ( >126 and < 240 mg/dl) at day 1, where FPG >13.3mM defines uncontrolled hyperglycemia, there were statistical significant differences between the treatment groups in the absolute

Start of Phase IIa proof-of-concept clinical trial of AMPK activator O304 in Type 2 Diabetics

Betagenon AB/Baltic Bio AB announces the start of Phase IIa proof-of-concept clinical trial of the first-in-class AMPK activator compound O304 in type2 diabetics.In the Phase I clinical trial O304 was administered to young healthy and to over-weight middle aged subjects and in combination with Metformin to subjects with Type 2 Diabetes (T2D). O304 did not cause any significant adverse effects, was very well tolerated and showed the expected pharmacokinetics. O304 also showed relevant metabolic and vascular effects.Thomas Edlund, CEO of Betagenon AB; “The Phase I trial established a safe

The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor

Low-density lipoprotein cholesterol (LDL-C),”bad” cholesterol, is considered a risk factor for cardiovascular disease s like heart attacks . LDL-C is removed from the blood upon binding to the LDL receptor (LDLR) present on the surface of liver cells , which results in uptake of LDL-C into the cells. The enzyme PCSK9 binds to and degrades the LDLR, thereby inhibiting removal LDL-C from blood. In man, gene variants with reduced expression or

First time in man-AMPK activator O304

Betagenon AB/Baltic Bio AB announces the initiation of Phase I clinical studies with O304, an orally available AMPK activator.The epidemic increase in obesity has generated a concomitant increase in fatty liver, non-alcoholic steato-hepatitis (NASH) and type 2 diabetes (T2D). Physical inactivity and T2D in elderly are in turn strongly associated with peripheral arterial disease (PAD), caused by reduced blood flow to the legs. Several 100 millions of patients globally live with NASH, T2D or PAD. There are very limited therapeutic options for NASH and PAD, and few new innovative drugs to

AMPK activator O304, 3-in-1 Drug

O304 acts like “Exercise in a Pill”, is anti-Diabetic and induces Brown Fat which disposes of excess calories as heatThe benefits of physical activity on general health especially in elderly, makes it a desirable, yet elusive goal to identify orally active drugs that would mimic the effects of exercise on endurance and on metabolic and other diseases. Similarly, drugs that could stimulate the disposal of excess calories/fat in the absence of exercise would be helpful in combating the epidemic increase in obesity that is associated with a western diet and sedentary life style. The generation

There are no items matching the current filter
There are no more items matching the current filter
Back to top